Q1 2018 EPS Estimates for Integra LifeSciences Holdings Corporation (IART) Lifted by Jefferies Group
Integra LifeSciences Holdings Corporation (NASDAQ:IART) – Equities researchers at Jefferies Group increased their Q1 2018 earnings estimates for shares of Integra LifeSciences in a research report issued on Monday. Jefferies Group analyst R. Denhoy now forecasts that the life sciences company will post earnings of $0.53 per share for the quarter, up from their previous estimate of $0.50. Jefferies Group currently has a “Buy” rating and a $56.00 price target on the stock. Jefferies Group also issued estimates for Integra LifeSciences’ FY2018 earnings at $2.30 EPS and Q1 2019 earnings at $0.61 EPS.
Other analysts have also issued research reports about the company. UBS restated a “buy” rating and set a $57.00 price target on shares of Integra LifeSciences in a report on Tuesday, October 31st. Oppenheimer restated a “buy” rating on shares of Integra LifeSciences in a report on Thursday, October 26th. Zacks Investment Research upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Tuesday, October 10th. TheStreet lowered Integra LifeSciences from a “b” rating to a “c+” rating in a report on Thursday, October 26th. Finally, Barclays restated an “equal weight” rating and set a $53.00 price target (up previously from $47.00) on shares of Integra LifeSciences in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $53.64.
Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences had a net margin of 4.52% and a return on equity of 16.35%. The company had revenue of $278.83 million for the quarter, compared to analysts’ expectations of $286.00 million. During the same quarter in the previous year, the company posted $0.93 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis.
A number of institutional investors have recently made changes to their positions in IART. Capital Research Global Investors grew its position in Integra LifeSciences by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after acquiring an additional 2,705,488 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Integra LifeSciences during the 2nd quarter worth $112,068,000. Koch Industries Inc. grew its position in shares of Integra LifeSciences by 12,623.4% during the 2nd quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock worth $741,000 after buying an additional 748,947 shares in the last quarter. Orbimed Advisors LLC grew its position in shares of Integra LifeSciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after buying an additional 664,000 shares in the last quarter. Finally, FMR LLC grew its position in shares of Integra LifeSciences by 6.2% during the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock worth $440,690,000 after buying an additional 468,678 shares in the last quarter. 87.62% of the stock is currently owned by institutional investors.
In other Integra LifeSciences news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction on Tuesday, October 31st. The stock was acquired at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the transaction, the director now directly owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. Corporate insiders own 21.50% of the company’s stock.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.